The aim of the study was to identify vitamin D accumulation properties in hospitalized COVID-19 patients, while also identifying changes in inflammatory markers for subjects taking vitamin D and the placebo group.
Protocol number of study: 2021sunD3 formula comparison
Start of study: 1 April 2021
End of study:1 June 2021
Head researcher: Prof. Valdis Pīrāgs
Inclusion criteria: men and women aged 18 to 65 with blood levels of vitamin D < 30 ng/ml, subject’s voluntary consent to participate in the study, the subject commits to not use other formulations containing vitamin D during the study.
The subjects were divided into 3 groups:
• The spray group consisted of subjects with a blood level of vitamin D of < 30 ng/ml, who took 4,000 IUs of vitamin D sublingually in spray form immediately after their morning meal, having first shaken the product well.
• The oil drop group consisted of subjects with a blood level of vitamin D of < 30 ng/ml, who took 4,000 IUs of vitamin D in oil drop form immediately after their morning meal.
• The capsule group consisted of subjects with a blood level of vitamin D of < 30 ng/ml, who took 4,000 IUs of vitamin D in capsule form immediately after their morning meal.
140 subjects were invited to the initial study interview, based on test results and exclusion criteria, 99 subjects qualified for the study and were divided into three groups at random with a similar number of subjects in each group.
Image 1. Overall changes in vitamin D concentration in the serum for subjects with BMI ≥ 25 kg/m2
Image 2. Overall changes in vitamin D concentration in the serum for subjects aged ≥ 50
• For overweight and obese individuals (BMI ≥ 25 kg/m2) with a vitamin D deficiency taking 4,000 IUs of vitamin D3 in spray form daily resulted in an average increase of 112% of their total vitamin D concentration in the serum over a period of only 30 days. (see Image 1).
• For the population aged ≥ 50 with a vitamin D deficiency taking 4,000 IUs of vitamin D3 in spray form daily resulted in an average increase of 95% of their total vitamin D concentration in the serum over a period of only 30 days. (see Image 2).
• Taken sublingually, vitamin D in spray form quickly enters the capillary bloodstream and is available to the body at a higher concentration, therefore it is recommended for eliminating in a rapid and controlled manned vitamin D deficiencies in people with a heightened risk of malabsorption, especially older overweight and obese individuals.